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The outcomes of adult acute lymphoblastic leukemia (ALL) patients with chemotherapy or autologous
hematopoietic stem cell transplantation (HSCT) are unsatisfactory. Therefore, allogeneic (allo) HSCT has been
applied to those patients in first complete remission (CR1), and has shown a long-term survival rate of
approximately 50 %. In terms of myeloablative conditioning (MAC) regimen, higher dose of cyclophosphamide
(CY) and total body irradiation (TBI) (the standard CY + TBI) has been generally applied to allo HSCT. Other
MAC regimens such as busulfan-based or etoposide-based regimens have also been used. Among those,
medium-dose etoposide (ETP) in addition to the standard CY + TBI conditioning regimen appears to be
promising for allo HSCT in adult ALL when transplanted in ALL patients aged under 50 years in CR1 and also
in CR2, showing an excellent outcome without increasing relapse or transplant-related mortality (TRM) rates.
By contrast, reduced-intensity conditioning (RIC) regimens have also been applied to adult ALL patients and
favorable outcomes have been obtained; however, relapse and TRM rates remain high. Therefore, an allo
HSCT conditioning regimen which deserves further study for adult ALL patients aged under 50 years in CR1
and CR2 appears to be medium-dose ETP + CY + TBI and RIC is suitable for patients aged over 50 years or for
younger patients with comorbid conditions. On the contrary, new therapeutic strategies for adult ALL patients
are increasingly utilized with better outcomes; namely, various tyrosine kinase inhibitors for Philadelphia
chromosome (Ph)-positive ALL, human leukocyte antigen-haploidentical HSCT, and pediatric-inspired regimens
for Ph-negative ALL. Therefore, the optimal treatment modality should be selected considering patient’s age,
Ph-positivity, donor availability, risk classification, efficacy, and safety.
Keywords: Acute lymphoblastic leukemia, Hematopoietic stem cell transplantation, Myeloablative conditioning
regimen, Reduced-intensity conditioning regimen, Cyclophosphamide, Etoposide, Total body irradiation,
Haploidentical HSCT, Philadelphia chromosome, Tyrosine kinase inhibitorIntroduction
Adult acute lymphoblastic leukemia (ALL) is a type of
intractable hematological malignancies, showing a long-
term survival rate of approximately 30 % with a high
incidence of relapse when treated with intensive chemo-
therapies [30, 53, 70, 74]. Allogeneic (allo) hematopoietic
stem cell transplantation (HSCT) from a human leukocyte
antigen (HLA)-matched donor has been applied to ALL* Correspondence: mimamura@med.hokudai.ac.jp
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therapy and autologous (auto) HSCT [23, 70], although
there is some controversy regarding the efficacy of allo
HSCT for ALL patients, especially for standard-risk pa-
tients [58, 70]. Although it was suggested that some
high-risk patients should be transplanted in first complete
remission (CR1) [58], standard-risk patients in CR1 had a
more beneficial effect by allo HSCT [23]. A similar result
was shown in another report that compared the efficacy of
allo HSCT versus auto HSCT for standard-risk adult ALL
patients in CR1, showing a 5-year (Y) disease free survivaless This article is distributed under the terms of the Creative Commons
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14 % versus 52 %, respectively [14]. Furthermore, a 5-Y es-
timated non-relapse mortality (NRM) rate was 16 % ver-
sus 2 %. These outcomes of allo HSCT for adult ALL
patients are unsatisfactory. Generally, long-term survival
rates of 40-60 % are obtained when both child and adult
high-risk patients in CR1 or second complete remission
(CR2) received allo HSCT by conventional myeloablative
conditioning (MAC) regimens [27, 34, 35, 42, 70]. The
outcome decreased depending on the remission status at
transplantation; namely, 40-60 % in CR1, 20-40 % in CR2,
10-20 % in ≧ third complete remission (CR3), and ap-
proximately 10 % in non-CR [5, 18, 26, 34, 35, 42, 47]. A
standard conventional MAC regimen for allo HSCT in pa-
tients with ALL is 120 mg/kg cyclophosphamide (CY) plus
12 to 13.2 gray (Gy) fractionated total body irradiation
(TBI). With this regimen, a 3-Y overall survival (OS) or
DFS rate of approximately 50 % was obtained when trans-
planted in CR1 [58, 70].
By contrast, reduced-intensity conditioning (RIC) regi-
mens have been applied to older patients and younger
patients with comorbid conditions. Fludarabine (Flu)-
based regimens are often utilized, showing an approxi-
mately 50 % OS rate; however, the frequencies of relapse
and complications following HSCT are relatively high.
Similar outcomes have been observed between RIC
and MAC regimens in the Philadelphia chromosome
(Ph)+ ALL patients who were minimal residual disease
(MRD)-negative when transplanted in CR1 [2]. Therefore,
RIC regimens are appropriate for patients aged ≧50 years
or those <50 years with serious comorbid conditions and
who are MRD-negative.
Recently, excellent outcomes have been obtained with
pediatric-inspired regimens for adult Ph− ALL patients
[15, 16] and also with HLA-haploidentical (haplo) HSCT
for ALL patients lacking an HLA-matched donor [1, 12,
40, 51, 54]. Furthermore, in Ph+ ALL patients, the
introduction of tyrosine kinase inhibitors (TKIs) has
revolutionized the treatment paradigm of Ph+ leukemia
patients [28, 38, 39, 50, 74], although these strategies
have some limitations. Therefore, it should be deter-
mined which type of treatment is optimal for each pa-
tient, considering patient’s age, Ph-positivity, donor
availability, risk, efficacy, and safety.
MAC regimens other than the CY + TBI regimen for adult
ALL patients
MAC regimens other than the CY + TBI regimen,
such as 60 mg/kg etoposide (ETP) + 12 - 13.2 Gy TBI
or 16 mg/kg busulfan (BU) + 120 mg/kg CY, were also
utilized in allo HSCT for hematological malignancies,
including ALL (Table 1) [6, 7, 25, 37, 49, 57, 59–61,
64, 66]. A single dose or a one-day dose of ETP was
generally used in ETP-based regimens. The outcome ofBU (oral) + CY regimen was not superior to that of CY +
TBI regimen. The outcome of ETP + TBI regimen was
similar to that of CY + TBI regimen, although ETP as a
substitute for CY is less immunosuppressive, resulting in
more frequent engraftment failure [57]. An early phase
I/II study for patients with advanced hematological ma-
lignancies of 33 patients with acute leukemia and 13
patients with ALL who were not in CR1, and 14 pa-
tients with other advanced hematological malignancies
showed that a single dose of 60 mg/kg ETP was the
maximal tolerated dose, as determined by relapse and
survival rates (15 % and 54 %, respectively) with the
dose ranging from 25 to 70 mg/kg [2].
Comparison of the medium-dose ETP + CY + TBI regimen
in the Hokkaido University Hospital with that in
French group
We tried to examine whether more intensified condition-
ing regimens of adding 10–25 mg/kg/day for 2 days of
ETP to the CY (60 mg/kg × 2) + TBI (2 Gy × 6) regimen
could improve the outcome of patients with hematological
malignancies since 1990 in the Hokkaido University Hos-
pital. Our preliminary study in the early 1990s showed
that higher ETP doses (20 and 25 mg/kg/day for 2 days)
were more toxic to the patients; therefore, we fixed the
ETP dose to 15 mg/kg/day for 2 days in 1993. Since then,
almost all of the patients with hematological malignancies
admitted to the Hokkaido University Hospital were
treated with this regimen. Ten years later, we recognized
that this regimen was more suitable for ALL (n = 11, the
5-Y OS: 100 %) as compared with total cases including
other hematological malignancies (n = 27, the 5-Y OS:
74 %) and that remission status was important for obtain-
ing a better outcome. A 5-Y DFS rate in CR1, CR2, and
non-CR were 91 %, 83 %, and 41 %, respectively [71].
In a retrospective analysis in which 37 ALL patients in
28 CR1, 7 CR2, and 2 non-CR were treated with allo
HSCT by a medium-dose ETP (15 mg/kg × 2) + CY
(60 mg/kg × 2) + TBI (2 Gy × 6) regimen, a 3-Y OS, re-
lapse, and transplant-related mortality (TRM) rate were
89 %, 8 %, and 5 %, respectively [59]. Among 10 Ph+
ALL patients transplanted in CR1, all patients were
alive, indicating that this regimen is markedly effective
even in high-risk Ph+ ALL patients. Six out of the ten
patients who were polymerase chain reaction-positive
for the bcr-gene rearrangement at transplantation became
MRD-negative after allo HSCT. Four other patients were
MRD-negative at transplantation. No patients received
TKIs before and after allo HSCT.
Then, we analyzed 515 patients aged 15–59 years who
received allo HSCT in CR1 or CR2 with CY (60 mg/kg ×
2) + TBI (12 Gy) or ETP (15 mg/kg × 2) + CY (60 mg/kg ×
2) + TBI (12 Gy) regimens between 1993 and 2007 by col-
lecting the clinical outcomes from the Japan Society for













aGVHD cGVHD Remarks Reference
ETP 60 mg/kg × 1
+ TBI 1.2 Gy × 11




15 % 31 % 23 % ND It was not clear whether ETP
60 mg/kg was better than
ETP 30 mg/kg according to a
phase I/II (dose-finding) study
using 25 to 70 mg/kg of ETP.
Blume KG, et al.
Blood 1987;69:1015.
ETP 50 to 70 mg/kg× 1
+ TBI 2 Gy× 6





6 % 35 % 85 % 50 % Anti-leukemic effect was
observed in a phase I/II study
with ETP + BI, but the rejection
rate was high. Thus, the
immunosuppressive effect was
worse than CY + TBI. A dose of
more than 60 mg/kg of ETP
was too toxic.
Schmitz N, et al.
Blood 1988;72: 1567.
ETP 36 mg/kg or
52 mg/kg × 1
+ CY 67 mg/kg or
103 mg/kg × 1 + TBI
2 Gy × 6
7 15 (6–35) MRD BM Relapse 0 % (≧899 d) ND ND ND ETP (36 mg/kg) + CY (67 mg/kg)
+ TBI was well tolerated for
allogeneic HSCT (phase I study).
Petersen FB, et al.
Bone Marrow Transplant.
1992; 10:83.
ETP 60 mg/kg × 1
+ TBI 1.2 Gy × 11
25/122 2–48 MRD BM CR2: 8 3-Y DFS: 63 % 8 % 4 % ND ND ETP + TBI appeared to be better
for a good-risk group than for a
poor-risk one according to a
randomized controlled study.
Hepatic toxicity and severe
mucositis were marked with ETP
of 60 mg/kg. The age range for
the patients with ALL was
shown, but the mean was
unclear.




12 % 40 % 12 % ND ND
BU 1 mg/kg × 16 + CY
60 mg/kg × 2
23/122 5–48 CR2: 6 4 % 17 % 4 % ND ND
CR3,
Non-CR: 17
17 % 34 % 22 % ND ND
ETP 60 mg/kg × 1
+ TBI 1.2 Gy × 11
34 27 (1–45) MRD BM CR1 3-Y DFS:
64 %
12 % ND 18 % (gr.≧II) 38 % A relatively good outcome was
observed in a phase II study,
but relapse and TRM rates were
high. Thirty of the 34 patients
were high-risk.









ETP 30–60 mg/kg ×
1 + CY 60–200 mg/kg ×
2 + TBI 1.2Gy × 11
(1.5 Gy × 8)




ND ND ND ND Fourty-four patients with
hematological malignancies
were analyzed in a retrospective
study. Among them, 20 patients
were ALL. Sixty to 65 mg/kg of
ETP resulted in a fatal toxicity,
but 30 to 50 mg/kg did not.
Fifty mg/kg of ETP was
considered to be the maximally
tolerated dose.
Spitzer TR, et al.
Int. J. Radiat. Oncol.
Biol. Phys. 1994;29:39
























Table 1 Myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for hematological malignancies, especially for acute lymphoblastic leukemia
(Continued)
Standard 20 (1–39) MRD BM CR2: 20 7-Y OS: 52 % 34 % 25 % 48 % (gr.≧II) 41 % A retrospective study suggested
that high-dose conditioning




Mengarelli A, et al.
Haematologica
2002;87:52.TBI 2 Gy × 6 + CY
120 mg/kg × 2
7/38 CR3: 9
1st Rel.: 5
Adv.: 4BU 16 mg/kg × 4
+ CY 120 mg/kg × 2
24/38
BU 16 mg/kg × 4
+ CY 120 mg/kg × 4
7/38
Alternative 23 (3–44) MRD BM: 60 CR2: 47 7-Y OS: 25 % 58 % 32 % 47 % (gr.≧II) 44 %
ETP 60 mg/kg × 1
+ TBI 2 Gy × 6 TBI
2 Gy × 6 + CY 120
mg/kg × 2
43/66 PB: 6 CR3: 9
1st Rel.: 6
Adv.: 13
BU 16 mg/kg × 4 + CY
120 mg/kg × 2 +IDA
42 mg/m2 × 2
BU-CY + VP
20 mg/kg × 1
BU-CY + Ara-C
2 g/m2 × 4
ETP 40 mg/kg × 1
+ CY 60 mg/kg × 2
+ TBI 2 Gy × 6
39 34 (15–52) MRD: 35 BM CR1 6-Y OS: 41 % 10 % 15 % ND ND Autologous HSCT by ETP + CY
+ TBI regimen showed 41 % of
6-Y OS in a prospective study,
whereas allogeneic BMT with
the same regimen showed a
6-Y OS of 75 %. This result
suggested a possibility of GVL
effect. ETP was administered in
4 consecutive infusions of
10 mg/kg lasting 2 hours each.
Hunault M, et al.
Blood 2004;104:3028.
MUD: 4 (<50 years
old: 75 %)
ETP 15 mg/kg × 2
+ CY 60 mg/kg × 2
+ TBI 2 Gy × 6





observed in addition to low
relapse and TRM rates in a
retrospective study.




MUD: 18 PB: 4 CR2: 7




















Table 1 Myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for hematological malignancies, especially for acute lymphoblastic leukemia
(Continued)
ETP 15 mg/kg × 2 + CY
60 mg/kg × 2 + TBI
2 Gy × 6 or 3 Gy × 4




A retrospective analysis in
Japan showed ETP + CY + TBI
was associated with lower
relapse and NRM rates,
resulting in better survival than
that with CY + TBI.
Shigematsu A, et al.
Int. J. Hematol.
2011;94:463.MUD: 11 PB: 6 CR2:7
MMUD: 6
Unknown: 2
CY 60 mg/kg × 2 + TBI
2 Gy × 6 or 3 Gy × 4








ETP 15 mg/kg × 2
+ CY 60 mg/kg × 2
+ TBI 2 Gy × 6






phase II study in Japan
confirmed the excellent
outcome of ETP + CY + TBI
for adult ALL patients.
Shimemastu A, et al.
Transplant. Direct.
2015;1:1MUD: 24 PB: 10 CR2: 3 2-Y OS: 67 %
1-Y EFS: 76 %
2-Y EFS: 65 %
No. the number of patients, ALL acute lymphoblastic leukemia, HSCT hematopoietic stem cell transplantation, TRM transplant-related mortality, NRM
non-relapse mortality, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host disease, ETP etoposide, TBI total body irradiation, MRD matched related donor, BM bone marrow, CR complete
remission, IF involved field, d day, ND not determined, CY cyclophosphamide, Auto autologous, BU busulfan, Y year, DFS disease-free survival, MUD matched unrelated donor, OS overall survival, GVL graft



















Imamura and Shigematsu Experimental Hematology & Oncology  (2015) 4:20 Page 6 of 15Hematopoietic Cell Transplantation (JSHCT) and the
Japan Marrow Donor Program (JMDP) data bases. A 5-Y
OS rate in CY + TBI and ETP + CY +TBI regimens were
55 % and 82 % (p = 0.003), respectively [61], suggesting
that ETP +CY + TBI regimen appears to be more benefi-
cial to adult ALL patients as compared with CY + TBI
regimen.
Another ETP (40 mg/kg in 8 h: 4 consecutive infu-
sions of 10 mg/kg lasting 2 h each) + CY + TBI regimen
was reported by a French group [25]. A 6-Y OS rate in
39 ALL patients aged < 50 years or 15–60 years, who re-
ceived allo BMT in CR1 was 75 % and 41 %, respectively,
whereas a 6-Y OS rate was 40 % in those who received
late high-dose chemotherapy followed by auto HSCT.
Major difference between ours and theirs are as fol-
lows: we used an ETP dose of 15 mg/kg/day × 2 days
and they used 40 mg/kg/day × 1 day. Furthermore,
they used bone marrow (BM) stem cells alone; by
contrast, among 37 patients, we used BM in 86 % of
the transplants, peripheral blood (PB) stem cells in
11 %, and cord blood (CB) stem cells in 3 %. The
outcome seems to be no difference in each stem cell
used. Our study had 69 % high-risk ALL patients, in-
cluding 27 % Ph+ patients [59], whereas their study
had 33 % high-risk ALL patients, including 21 % Ph+
patients. Although they used only an HLA-matched
sibling donor, we used an HLA-matched related or
unrelated donor and an HLA-mismatched related or
unrelated donor.
A prospective multi-center phase II clinical trial with the
medium-dose ETP + CY + TBI regimen for adult ALL patients
in Japan
A prospective multi-center phase II clinical trial has
been conducted in Japan to validate whether the
medium-dose ETP + CY + TBI regimen is an excellent
conditioning regimen for ALL patients in CR1 and CR2.
The sequential order of each agent was not always fixed
depending on the physician’s discretion. Of the 50 pa-
tients (47 CR1 and 3 CR2), 84 % were high-risk patients,
including 38 % Ph+ patients. A 1-Y OS, EFS, relapse, and
NRM rate were 80 %, 76 %, 10 %, and 14 %, respectively
[60]. Furthermore, an estimated 2-Y OS, EFS, relapse,
and NRM rate were 67 %, 65 %, 15 %, and 20 %. The re-
lapse rate in the recent study was slightly higher than
the previous rate (10 % at 1 year and 15 % at 2 years ver-
sus 8 % at 3 years); it was 10 % at 6 years in the French
group study [25]. Although the 1- and 2-Y NRM rates
(14 % and 20 %) in the recent study were higher than
the 3-Y TRM rate (6 %) in the previous one, these rate
was comparable with that of the French group study
(15 %) [25]. Therefore, these results strongly confirm that
this regimen is remarkably effective for adult ALL patients
in CR1, showing a higher OS rate without increasingTRM/NRM and relapse rates. The outcome was not influ-
enced by the difference of donor type (related versus unre-
lated), age difference (≧40 years old versus < 40 years old),
stem cell source (BM versus PB), Ph-positivity (positive
versus negative), risk group (high versus standard), or dis-
ease status (CR1 versus CR2). TKIs were used in Ph+ ALL
patients only before allo HSCT. All patients were
engrafted with median neutrophil recovery (≧500/μl) at
day 16, similar to the result of the previous report [59].
No patients died within 100 days.
Acute and chronic graft-versus-host disease (GVHD)
generally developed at rates of 20–40 % (grade ≧II:
approximately 20 %) and 30–50 % (extensive type: ap-
proximately 30 %) in MAC regimens, respectively [2,
6, 7, 57, 59–61, 64]. The occurrence of acute GVHD
in the medium-dose ETP + CY + TBI regimen appears
to be more frequent (66 %). Although grade ≧II acute
GVHD were observed in 58 % of transplants, uncontrol-
lable severe acute GVHD was not observed. Chronic
GVHD was observed in 56 % of patients (extensive type:
41 %), showing a slightly more frequent incidence. In
Japan, we use both related and unrelated HLA-matched
donors (approximately 35 % and 50 %, respectively),
whereas HLA-matched sibling donors were generally se-
lected in other ETP-based regimens in Western countries.
The outcome of allo HSCT from an HLA-matched
unrelated donor is almost the same as that from an
HLA-matched related donor in Japan [26]. This favor-
able phenomenon may be due to Japanese genetic
homogeneity [43, 44, 48, 55]. Furthermore, although
we use HLA-mismatched related donors in approxi-
mately 5 % of transplants and HLA-mismatched unre-
lated donors in approximately 10 % of transplants, no
unfavorable outcome was observed.
The upper age limit for allo HSCT is thought to be
50–55 years, although we performed allo HSCT in an
ALL patient aged 58 years using the medium-dose
ETP + CY + TBI regimen. When the patient was older,
severe complications developed more often. Therefore,
the medium-dose ETP + CY + TBI regimen appears to
be appropriate for patients aged < 50 years because of
its toxicity. In fact, the outcomes of RIC and MAC in
allo HSCT for adult ALL patients aged ≧45 years
were analyzed in the adult ALL Working Group of
the JSHCT, suggesting that patients aged ≧50 years
should be transplanted by RIC regimens [69].
A TRM rate of only 5 % by the medium-dose ETP +
CY + TBI regimen was observed in ALL patients aged
15–58 years (54 % were from < 40-years-old patients) in
our previous study [59], and a NRM rate of 14 % was
observed in ALL patients aged 17–49 years in our re-
cent study [60]. Such low TRM/NRM rates in adult
ALL patients are remarkable when compared with other
ETP-based regimens, in which higher doses of ETP were
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to be due to the divided administration of a lower dose
of ETP and relatively younger patients enrolled (54 %
were < 45-years-old). Even if lower doses of ETP were
used, the relapse rate remained < 10 %. Furthermore, no
patients developed second malignancies after a median
follow-up period of 90 months as of June, 2014. This
finding is supported by the fact that the cumulative
risk factor after 15 years was 1.26 % in 366 out of
1376 ALL patients who received allo HSCT with frac-
tionated TBI + ETP 40–60 mg/kg [8].
Although CB was not used in the present phase II trial,
a similar outcome between CB and other stem cells is ex-
pected with the medium-dose ETP + CY + TBI regimen as
shown in several studies [20, 31, 52, 68].
ETP-based conditioning regimens were also used in
child and adolescent ALL patients [19, 72]. The ETP doses
were comparable with our regimen; however, most of the
patients were transplanted at advanced stages and ETP
was administered in a single dose, resulting in higher
TRM rates.Outcome of Ph+ adult ALL patients transplanted with
allogeneic HSCT
Although some Ph+ ALL patients were included in
each trial shown in Table 1, the outcome of allogen-
eic HSCT for only Ph+ ALL patients is shown in
Table 2 [4, 17, 21, 22, 29, 62, 65, 75]. Ph+ALL pa-
tients who received allo HSCT after conditioning regi-
mens excluding ETP had a poor prognosis. ETP
(higher doses: 50–60 mg/kg)-based conditioning regi-
men improved the outcome to some extent. However,
the relapse and TRM/NRM rates remained high.
On the contrary, the introduction of TKIs in com-
bination with chemotherapies has drastically changed
the outcomes of Ph+ALL patients, resulting in in-
creased CR rate compared with historical controls.
However, since the probability of relapse remains
high, allo HSCT in CR1 is required to obtain a better
outcome. There are several reports regarding the effi-
cacy of imatinib (IM) use before allo HSCT with 2-Y
- 5-Y OS of 40–78 % [28, 33, 38, 50, 74].
In terms of IM use in ALL patients after allo
HSCT, a 5-Y DFS in prophylactic arm and in MRD-
triggered arm was 84 % and 60 % (p = 0.89), respec-
ticvely and a 5-Y OS was 80 % and 75 % (p = 0.84),
respectively [50]. Although prophylactic use of IM
significantly reduced the incidence of molecular re-
currence after allo HSCT compared with MRD-
triggered use of IM (40 % versus 69 %, p = 0.046), the
outcome was shown to be no difference between both
arms. Relapse probability was significantly higher in
patients who became MRD-positive (p = 0.017).By contrast, neither TKI use pre- nor post-allo
HSCT was found to significantly impact outcomes
[28]. However, this is a retrospective study and there
are some limitations regarding the heterogeneity in
conditioning regimens, allotype, and stem cell source,
as well as the small sample size.
Therefore, the outcome of chemotherapy combined
with TKIs followed by allo HSCT in CR1 with MAC
regimens other than ETP-based regimens appears to
be not always superior to that of allo HSCT per-
formed by using the medium-dose ETP + CY + TBI
regimen. It is meaningful to evaluate whether admin-
istration of other TKIs pre- or post-allo HSCT is
beneficial for the outcome of Ph+ ALL patients by the
prospective clinical trial in the future.
Importance of administration schedule of ETP
The administration schedule of ETP is an important
factor for reducing adverse effects, although it depends
on combined chemotherapy and/or TBI. We used a 3-h
infusion on 2 consecutive days with 30 mg/kg of ETP,
whereas 60 mg/kg of ETP was usually administered in a
single dose of a 4-h infusion [2, 6, 7, 64]. The max-
imally tolerated dose (MTD) is thought to be 2.4 g/m2
in 1 to 1.5-h infusions on 3 consecutive days, with
4.2 g/m2 as continuous infusion (29 to 69-h) [9, 24].
When ETP, CY, and TBI were combined, the MTDs
were 1.8 g/m2 for ETP, and 180 mg/kg for CY.
Possible mechanisms of efficacy of the medium-dose
ETP + CY + TBI
It is important to clarify how the medium-dose ETP +
CY + TBI regimen can eradicate residual leukemic cells
more efficiently than the CY + TBI regimen or others.
The graft-versus-leukemia (GVL) effect is hardly observed
against ALL; however, allo HSCT is superior to auto
HSCT in terms of the outcome [18, 23, 70]. Furthermore,
chronic GVHD appears to induce a GVL effect in ALL pa-
tients [32], although others could not confirm a decreased
relapse risk in the higher incidence of chronic GVHD
among the recipients of allo PB [10, 56].
ETP upregulated the expression levels of interleukin
(IL)-8 and macrophage inflammatory protein-1α in pro-
monocytic acute myelogenous leukemia cells, most likely
inducing an enhancement of the anti-leukemic effect [45].
A low dose of ETP can enhance leukemia rejection in
mice by rendering them immunogenic and susceptible to
CD8+T cell deaths [63]. Several immunomodulations by
ETP are also observed in other tumor cells [73]. A prelim-
inary in vitro study showed that CY synergized with ETP
in terms of cytotoxic effect against leukemic cells (unpub-
lished observation). Indeed, it is known that ETP exhibits
a synergy with 4-hydroperxycyclophosphamide against a
promyelocytic leukemic cell line determined by in vitro
Table 2 Myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia











TRM/NRM aGVHD cGVHD Remarks Reference
ETP 60 mg/kg × 1
+ TBI 1.2 Gy × 11
5 28 (23–45) MRD BM CR1: 4 OS: 60 %
(≧171 d)
0 % 40 % 50 %
(gr.≧II: 33 %)
ND Intensified conditioning regimens
followed by allogeneic HSCT were
a preferred treatment modality





ETP 60 mg/kg × 1
+ TBI 7.5 Gy × 1
1
Non-CR: 6
CY 100 mg/kg × 1
+ TBI 1.2 Gy × 11
3
BU 1 mg/kg × 16
+ CY 60 mg/kg × 1
1
BU + CY +TBI 67 28 (5–49) MRD BM CR1: 33 2-Y DFS: 38 % 34 % CR1: 42 % Gr.≧II: 24 % 33 % Allogeneic HSCT was feasible for
Ph+ ALL patients according to a
retrospective study using IBMTR
data. The dose of conditioning





Rel: 22 2-Y DFS: 41 % 32 % Rel: 40 % : 38 % 31 %
IF: 12 2-Y DFS: 25 % 57 % IF : 42 % : 45 % 22 %
CY 60 mg/kg × 2
+ TBI 1.2 Gy × 11
(for patients ≧18 y)





were useful when related
HLA-matched donors were not
found in a retrospective study.
Sierra J, et al.
Blood 1997;
90:1410.
CY 60 mg/kg × 2





ETP 50 mg/kg× 1
+ TBI 1.2 Gy× 11
+/–CY 60 mg/kg x 2
22 30 (6–42) MRD BM/PB CR1 3-Y DFS: all 65 % 12 % 30 % 65 % 65 % The relatively low relapse rate
might reflect the enhanced
anti-leukemic activity of ETP/TBI
compared to other conditioning





13:2053.CY 60 mg/kg × 2
+ TBI 1.2 Gy × 11
1
<1992 : 45 %
≧1992: 81 %
ETP 50 mg/kg × 1
+CY 60 mg/kg × 2
+TBI 2 Gy × 6 or
TBI 10 Gy × 1
74 42 (17–56) MRD: 43 BM CR1 2-Y OS: 37 % 40 % 67 % ND ND Allogeneic HSCT in CR1 was the
best treatment option in Ph+ ALL
according to a prospective study.
Outcome was better in bcr/abl
transcript-negative patients than
in bcr-abl transcript-positive ones.
The 2-Y OS, relapse, and TRM rates
were 26 %, 74 %, and 91 %,




2002;100:2357.MUD: 8 2-Y OS: 63 % 25 % 38 % ND ND
CY 60 m/kg × 2
+ TBI 2Gy × 6
(for adults)




A better outcome was correlated
with remission status at transplant
in a prospective study. The relapse
rate decreased with the occurrence
of acute GVHD. Bcr/abl transcript-








or 6 + Mel
140 mg/m2 × 1
+TBI 2 Gy × 6
(for children)























Table 2 Myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia
(Continued)
CY 60 mg/kg × 2
+ TBI 2 Gy × 6
166 37 (16–59) MRD: 136 BM: 167 CR1: 93 5-Y OS N.D. N.D. N.D. N.D. Allogeneic HSCT was the only
procedure with curative potential
for Ph+ ALL according to a
retrospective study. Pre-transplant
disease status was an important
factor for better survival. Extensive
cGVHD correlated with a better








31 MUD: 61 PB: 24 :>CR1 19 CR1: 34 %
BM+PB: 6 Non-CR: 85 >CR1: 21 %
5-Y OS
TBI (n = 166):
25 %
Non-TBI
(n = 31): 8 %
ETP 60 mg/kg × 1
+TBI 1.2 Gy × 11




Disease status at the time of HSCT
was important according to a
retrospective study. ETP + TBI with
or without CY conferred long-term
survival. Seventeen patients received
imatinib before HSCT and received




ETP 60 mg/kg× 1
+ CY 60 mg/kg× 2
+ TBI 1.2 Gy× 11
11
PB: 36 >CR1:30 CR1: 48 % CR1: 28% >CR1: 54 %
ETP 60 mg/kg× 1
+BU 1 mg/kg× 16
+TBI 1.2 Gy× 11
1
>CR1: 29 % >CR1: 41 %
No. the number of patients, ALL acute lymphoblastic leukemia, HSCT hematopoietic stem cell transplantation, TRM transplant-related mortality, NRM non-relapse mortality, aGVHD acute graft-versus-host disease, cGVHD chronic
graft-versus-host disease, ETP etoposide, TBI total body irradiation, CY cyclophosphamide, BU busulfan, MRD matched related donor, BM bone marrow, CR complete remission, OS overall survival, d day, gr. grade, ND not determined,
































Relapse rate TRM/NRM aGVHD cGVHD Remarks Reference
Flu 90–150 mg/m2 +
Mel 140 mg/m2





Martino R, et al.
Haematologica
2003;88: 555.
Flu + Mel+ Ara-C
2 g/m2
MMRD PB CR2/3:10 GVHD+: 35 % Limt.: 39 %
Flu + 2 Gy TBI





Flu + CY 60 mg/kg+
Thiotpa 10 mg/kg
Flu 30 mg/m2 × 6
+4 Gy TBI/ATG
10 mg/kg/d × 4







Mohty M, et al.
Haematologica
2008; 93: 303.
Flu + BU 8 mg/kg
MUD PB CR2/3: 30 27 % 63 % CR2/CR3, NRM:
17 %
Flu + Mel
Non-CR: 39 20 % 49 %
More advanced
stage, NRM: 44 %
Flu + CY
Flu 25 mg/m2 × 5+
Mel 140 mg/m2 × 1
















MUD CR2: 5 Limit.: 21 %
≧CR3: 3 Ext.: 54 %
Non-CR 5
Flu 40 mg/m2 × 5+
















MUD CB ≧CR2: 10 Gr.≧III: 20 % Ext.: 32 %
Flu 30 mg/m2 × 5
+Mel 70 mg/m2 × 2
+/−ATG 2.5 mg/kg








Cho B-S, et al.
Leukemia
2009;23:1763.MUD BM CR2: 7 Limit: 28 %



















Table 3 Reduced-intensity conditioning regimens in allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia (Continued)
BU 9 mg/kg or less +
Mel 150 mg/m2 or
less+ TBI >5 Gy or
fractionated
93 45 (17–66) MRD: 30 PB: 68 CR1: 55 3-Y OS:
38 % (RIC)
35 % (RIC) RIC TRM rate in RIC
was almost the












MUD: 36 BM: 25 CR2: 38 3-Y OS: 43 %
(MAC)
26 % (MAC) TRM: 32 % Gr.≧II: 39 % 34 %







3-Y DFS: 41 %
(MAC)
TRM: 33 % Gr.≧II: 46 % 42 %
UD: 2
No. the number of patients, ALL acute lymphoblastic leukemia, HSCT hematopoietic stem cell transplantation, TRM transplant-related mortality, NRM nonrelapse mortality, aGVHD acute graft-versus-host disease, cGVHD
chronic graft-versus-host disease, Flu fludarabine, Mel melphalan, Ara-C cytosine arabinoside, Gy gray, TBI total body irradiation, CY cyclophosphamide, MRD matched related donor, MMRD mismatched related donor,
MUD matched unrelated donor, MMUD mismatched unrelated donor, BM bone marrow, PB peripheral blood, CR complete remission, PR partial remission, Y year, OS overall survival, gr. grade, Limit. limited type of
cGVHD, Ext. extensive type of cGVHD, GVL graft-versus-leukemia, ATG anti-thymocyte globulin, BU busulfan, Ph Philadelphia chromosome, RIC reduced-intensity conditioning, CB cord blood, PMMUD partially
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anisms may be responsible for the superiority of the
medium-dose ETP + CY + TBI regimen in ALL patients.
Reduced-intensity conditioning regimens for adult
ALL patients
As shown in Table 3, various RIC regimens for allo
HSCT were applied for adult ALL patients [3, 13, 35,
36, 41, 67]. The stem cell source was mainly either
BM or PB from an HLA-matched or mismatched re-
lated and an HLA-matched or mismatched unrelated
donor. The 2-Y or 3-Y OS were 30-60 %. A better
outcome was observed in patients transplanted in
CR1 compared with those transplanted in more ad-
vanced stages. The relapse rates were 20–60 %. The
TRM/NRM rates were 20–40 %. The occurrence of acute
GVHD (≧grade II) and chronic GVHD was 40–60 % and
30–70 % (extensive type: 30–50 %), respectively. GVL ef-
fect against ALL could be induced by RIC regimens and
allo HSCT with RIC regimens was feasible for patients
with high-risk ALL patients in remission [36]. It is notable
that the relapse rate in the RIC regimen for adult Ph− ALL
patients in Japan was higher (26 % vs 10 %) than that in
the medium-dose ETP +CY +TBI regimen [46, 60].
Pediatric-inspired regimens for adult Ph− ALL patients
Pediatric-inspired regimens resulted in a better out-
come for adult Ph− ALL patients aged 15–55 years
regardless of undergoing allo HSCT in CR1 [16]. Al-
though CY + TBI conditioning regimen was used for
allo HSCT, a 3-Y relapse rate, NRM, and relapse-free
survival (RFS) were 20 %, 16 %, and 65 %, respect-
ively. Of the allo HSCT patients, a 3 Y-NRM in the
patients aged 45–55 years and those aged 15–44 yearsTable 4 Possible treatments for adult ALL patients by Ph-positivity,
Ph Age (years) Induction therapy MRD Allo HSCT
− <45 Pediatric-inspired Chemotherapy + Allo HSCT with
case of lacking
No HSCT
45–50 Conventional chemotherapy Allo HSCT with
case of lacking
≧50 Conventional chemotherapy − Allo HSCT with
HLA- matched
+ <45 Conventional or pediatric-inspired
chemotherapy + TKI
Allo HSCT with
of lacking an H
45–50 Conventional chemotherapy + TKI Allo HSCT with
case of lacking
≧50 Conventional chemotherapy + TKI − Allo HSCT with
donor in CR1)
ALL acute lymphoblastic leukemia, Ph Philadelphia chromosome, MRD minimal resid
body irradiation, CR complete remission, HLA human leukocyte antigen, Haplo HSCT
myeloablative conditioning, RIC reduced-intensity conditioning, TKI tyrosine kinasewas 26 % and 13 % (p < 0.048), respectively. A 3-Y
RFS in the younger and the older was 67 % and 56 %
(p < 0.12), respectively and a 3-Y OS was 72 % and
61 % (p < 0.082), respectively.
Almost comparable outcomes were observed in pa-
tients with allo HSCT and those without allo HSCT,
although the survival in patients with MRD (≧1−3) at
6 weeks after induction initiation was longer in the
allo HSCT cohort than in the no HSCT cohort. These
results indicate standard risk ALL patients aged < 40–
45 years with MRD (<1−3) at 6 weeks after induction
initiation may not require allo HSCT in CR1. A simi-
lar result has been also shown in other study [15]. In
the future, it should be determined whether the
medium-dose ETP + CY + TBI regimen is suitable for
adult standard risk ALL patients aged < 40–45 years
based on MRD analysis.
HLA-haploidentical hematopoietic stem cell
transplantation for adult ALL patients
Recently, haplo HSCT, which is varied in the settings,
has been increasingly performed [51]. Basically, this pro-
cedure is still alternative for the patients lacking an
HLA-matched related donor, since the outcomes are ap-
proximately 20–50 % and limited numbers of ALL cases
are reported. In patients with ALL, AML, and other
hematological malignancies transplanted with mostly T
cell-depleted PB, DFS, relapse rate, and TRM rate were
20–50 %, 20–60 %, and 30–40 %, respectively. The out-
comes in ALL patients were generally inferior to those
in AML patients [1].
Among several haplo HSCT, the following method ap-
pears to be excellent for ALL patients. Adult Ph− ALL
patients (n = 183) in CR1 received unmanipulated haploage, and MRD-positivity
medium-dose ETP + CY + TBI in CR1/2 (Haplo HSCT with MAC in the
an HLA-matched donor in CR1)
medium-dose ETP + CY + TBI in CR1/2 (Haplo HSCT with MAC in the
an HLA-matched donor in CR1)
RIC in CR1 (Haplo HSCT with RIC in the case of lacking an
donor in CR1)
medium-dose ETP + CY + TBI in CR1 (Haplo HSCT with MAC in the case
LA-matched donor in CR1)
medium-dose ETP + CY + TBI in CR1/2 (Haplo HSCT with MAC in the
an HLA-matched donor in CR1)
RIC in CR1 (Haplo HSCT with RIC in the case of lacking an HLA-matched
ual disease, Allo allogeneic, ETP etoposide, CY cyclophosphamide, TBI total
HLA-haploidentical hematopoietic stem cell transplantation, MAC
inhibitor
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(G-CSF) for all donors, intensive immune suppression,
anti-thymocyte globulin, and combination of G-CSF-
primed BM and G-CSF-mobilized PB. A 3-Y relapse
mortality and NRM for high risk versus low risk groups
were 7 % versus 11 % (p = 0.498) and 18 % versus 16 %
(p = 0.717), respectively. A 3-Y DFS and OS for high risk
and low risk were 67 % versus 68 % (p = 0.896) and 75 %
versus 73 % (p = 0.981), respectively [40].
The same group reported that the outcome of haplo
HSCT for Ph+ ALL patients (n = 101) is comparable to
that of HSCT (n = 38) from an HLA-matched related
donor. A 5-Y DFS, OS, relapse, and NRM rates in the
haplo HSCT group were 66 %, 74 %, 20 %, and 16 %, re-
spectively. Acute (grade ≧II) GVHD was higher (32 %
versus 16 %, =0.045) in the halpo HSCT than in the con-
trol group, although there was no difference between
both groups in chronic GVHD frequency (extensive
type: 20 % versus 13 %) [12].
Ruggeri et al. [54] reported that no statistically sig-
nificant differences were observed between haplo
HSCT and CB transplantation for a 5-Y relapse (ap-
proximately 40 %), NRM (approximately 30 %), and
LFS (approximately 30 %). The outcomes were not so
excellent probably due to the inclusion of many pa-
tients not in CR1. However, this strategy is valid for
ALL patients lacking an HLA-matched donor.
Conclusions
In allo HSCT, the medium-dose ETP + CY + TBI regi-
men is promising for high-risk ALL patients aged <
50 years in CR1 and also for standard-risk patients in
CR2, resulting in an excellent outcome without higher
TRM and relapse rates. However, the enrolled case for
the prospective multi-center phase II clinical trial with
the medium-dose ETP + CY + TBI regimen for adult
ALL patients in Japan is still small and a prospective
randomized phase III clinical trial is required for deter-
mining its genuine efficacy in the future. On the con-
trary, RIC for adult ALL patients is preferable to older
patients aged ≧50 years or younger patients with ser-
ious comorbid conditions and who are MRD-negative.
Furthermore, recently developed various therapeutic
strategies such as haplo-HSCT, pediatric-inspired regi-
mens, and use of TKIs at pre- or post-allo HSCT for
adult ALL patients should be taken into consideration
to obtain a better clinical outcome (Table 4).
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